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A B S T R A C T
For the creation of scaffolds in tissue engineering applications, it is essential to control the physical
morphology of ﬁbres and to choose compositions which do not disturb normal physiological function.
Collagen, the most abundant protein in the human body, is a well-established biopolymer used in
electrospinning compositions. It shows high in-vivo stability and is able to maintain a high biomechanical
strength over time. In this study, the effects of collagen type I in polylactic acid-drug electrospun scaffolds
for tissue engineering applications are examined. The samples produced were subsequently
characterised using a range of techniques. Scanning electron microscopy analysis shows that the ﬁbre
morphologies varied across PLA-drug and PLA-collagen-drug samples  the addition of collagen caused a
decrease in average ﬁbre diameter by nearly half, and produced nanoﬁbres. Atomic force microscopy
imaging revealed collagen-banding patterns which show the successful integration of collagen with PLA.
Solid-state characterisation suggested a chemical interaction between PLA and drug compounds, irgasan
and levoﬂoxacin, and the collagen increased the amorphous regions within the samples. Surface energy
analysis of drug powders showed a higher dispersive surface energy of levoﬂoxacin compared with
irgasan, and contact angle goniometry showed an increase in hydrophobicity in PLA-collagen-drug
samples. The antibacterial studies showed a high efﬁcacy of resistance against the growth of both E. coli
and S. Aureus, except with PLA-collagen-LEVO which showed a regrowth of bacteria after 48 h. This can be
attributed to the low drug release percentage incorporated into the nanoﬁbre during the in vitro release
study. However, the studies did show that collagen helped shift both drugs into sustained release
behaviour. These ideal modiﬁcations to electrospun scaffolds may prove useful in further research
regarding the acceptance of human tissue by inhibiting the potential for bacterial infection.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Within the ﬁeld of tissue engineering, there are a number of
different applications that can be explored relating to the
combination of synthetic and natural polymers, and integration
with various active pharmaceutical ingredients. For example,
surgical wound closure involves the bringing together of opposing
surfaces using glues, staples and/or sutures. The re-joined tissues
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then undergo a primary hyper-proliferative stage, characterised by
clot formation and the recruitment of inﬂammatory cells (macro-
phages) into the wound (Koh and DiPietro, 2011). Secretion of local
tissue mediators encourages cell migration and begins the process
of scar formation (Hu et al., 2014). Wound contraction, a result of
tissue remodelling, increases the tensile strength of skin across
lesions and increases (or decreases) the risk of ruptures. During the
healing stage, the tissue is open to infection itself and as a pathway
into deeper tissue structures. Infection can result in signiﬁcant
complications (e.g. prolonged systemic antibiotic administration,
re-operation for debridement) for the patient in the short and
long-term. In supporting healing, the purpose of an added matrix
task may be to provide tensile strength, to encourage controlled
epithelialisation and new vascular growth and to decrease the
formation of bacterial bioﬁlms. The fabrication of scaffolds for
wound repair has become important, especially the formation of
tissue-speciﬁc scaffolds (van Winterswijk and Nout, 2007).
For the creation of scaffolds it is essential to mimic the chemical
composition, the physical morphology, and the biological func-
tions of the human body (Jiang et al., 2013). Scaffolds can be
created using synthetic polymers (e.g. polycaprolactone) or natural
polymers (e.g. chitosan), or a combination of both  the addition of
natural polymers can be highly advantageous as these may avoid
the stimulation of chronic inﬂammation, immunological reactions
and toxicity (Mano et al., 2007). An example of a natural polymer is
collagen, which is the most abundant protein in the human body, a
key element of the extracellular matrix (ECM), and imparts
structural integrity and tensile strength to tissues (Sell et al., 2009).
Using collagen in scaffolds has been previously shown to show a
high in vivo stability and is able to maintain a high biomechanical
strength over time (Tillman et al., 2009).
One method that is commonly used to fabricate scaffolds for
tissue engineering is electrospinning. The technique utilises
electrostatic forces to stretch a dilute polymer solution as it
solidiﬁes (Del Valle et al., 2011). It is an ideal micro- and nanoﬁbre
fabrication technique for tissue engineering, as the ﬁbres within
the resulting scaffold closely mimic the size and structure of the
native extracellular matrix (Tan et al., 2008) and the use of solvent
and aqueous based systems are useful for the integration of
biological compounds, such as collagen. Various practices of
electrospinning collagen, including collagen-elastin blends (But-
tafoco et al., 2006), collagen-polycaprolactone scaffolds for
vascular tissue engineering (Venugopal et al., 2005), and ﬁbrino-
gen ﬁbres which allows native deposits of collagen during cell
growth (McManus et al., 2006) have previously been studied.
Despite these examples of electrospinning involving collagen,
there is an apparent gap in the research concerning the integration
of drugs in these electrospun scaffolds. The integration of drugs,
such as antibiotics, with polymer-collagen blends may be critical in
the future success of human tissue accepting the scaffolds; there
are many clinical applications for scaffolds that require controlling
growth of bacteria. For example, one of the requirements for
controlling intra-abdominal infection is to maintain satisfactory
levels of an antimicrobial drug during drug administration
(Solomkin et al., 2010). In this regard, the sustained release of
drugs is critical to the success of the device. Sustained release of
drugs with electrospun materials have been previously studied,
including polylactic acid with diclofenac sodium (an anti-
inﬂammatory agent) (Toncheva et al., 2011), metronidazole-loaded
polycaprolactone nanoﬁbres (He et al., 2016), and polyvinylidene
ﬂuoride with enroﬂoxacin (antibiotic) (He et al., 2015). Given the
range of success there has been with electrospinning polymer with
drug, and polymer-collagen blends, the next area of research
should be to determine whether we can alter any of the
characteristics of scaffolds with the inclusion of collagen, whether
it be mechanical, chemical or drug release changes.
The purpose of this study is to examine the physicochemical
properties, bacterial response, drug loading and bio-functionalisa-
tion of electrospun scaffolds that have been prepared using Type I
Collagen with a supporting synthetic polymer. The polymer chosen
for this study is Polylactic-acid (PLA), a biodegradable and
biocompatible polymer. It has been approved by the US Food &
Drug Administration for safe clinical use as resorbable sutures
(Kimura and Ogura, 2001). PLA has also been used clinically for foot
fractures (PLA pins) (Athanasiou et al., 1996), temporary implants
(Nair and Schug, 2004) and drug delivery carriers (Ramot et al.,
2016). In this study, solutions were modiﬁed by the addition of
type I collagen. The matrix was loaded and electrospun with two
drugs, triclosan (an antibacterial agent used commonly in soaps,
detergents and surgical cleaning agents) or levoﬂoxacin (a broad-
spectrum quinolone antibiotic used commonly in clinical practice
to treat gastrointestinal infections). The electrospun ﬁbres were
then characterised through various methods: the morphology of
the electrospun ﬁbres was characterised by scanning electron
microscope (SEM) and Atomic Force Microscope (AFM), solid state
characterisation was performed by x-ray powder diffraction
(XRPD) and differential scanning calorimetry (DSC), surface
characterisation of the two drugs was investigated by surface
energy analysis (SEA) and contact angle goniometry (CAG), and
drug efﬁcacy (e.g. in vitro release studies, antibacterial studies and
time-of-ﬂight secondary ion mass spectrometry (ToF-SIMS)). The
results from this study should help to build a proﬁle of data in order
to aid future work with regards to tissue engineering research
speciﬁc to the controlled release of drugs.
2. Materials & methods
2.1. Materials
Polylactic acid (PLA) with a mixed molecular weight was the
chosen polymer for this study and was used as purchased from the
suppliers (Sigma-Aldrich, GF45989881), and the collagen used was
type I from calf skin (Sigma-Aldrich, C9791). Irgasan (5-Chloro-2-
(2,4-dichlorophenoxy)phenol), Triclosan, >97%, (Sigma-Aldrich,
72779) and levoﬂoxacin ((S)-9-ﬂuoro-2,3-dihydro-3-methyl-10-
(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxa-
zine-6-carboxylic acid) >98%, (Sigma-Aldrich, 28266) were
obtained commercially. The solvents used for the electrospinning
were also commercially purchased from Sigma-Aldrich, speciﬁcal-
ly chloroform (anhydrous, containing amylenes as stabilizers
grade, >99%), N,N-dimethylformamide (DMF, anhydrous grade
99.8%) and 1,1,1,3,3,3-hexaﬂuoro-2-propanol, (GC grade >99%).
2.2. Preparation of PLA solutions
Investigations of the polymer-drug solutions prepared showed
that the optimum w/w concentration for electrospinning was 8%.
This particular concentration was used as previous experimenta-
tion revealed that higher concentrations did not result in suitable
ﬁbre formation (suitable meaning regular ﬁbre diameters and no
signs of beading, data not shown). PLA (8% w/w), and a 9:1 (w/w)
ratio of chloroform (CLF) to N,N-dimethylformamide (DMF). For
the formulations containing collagen type I, both polymers were
solubilised in hexaﬂuoropropanol (HFP) with a total polymer
(collagen + PLA) concentration of 8%. PLA was blended with
collagen containing 1% collagen (MPLA/[MCollagen+ MPLA] x 100)
(Powell and Boyce, 2009). Collagen at a 1% concentration was
used as higher concentrations, in the range 2% to 10% w/w, yielded
unstable and inconsistent ﬁbre formations.
The solutions were mixed through 30 min in the centrifuge, a
further 30 min in a sonicator and a ﬁnal 1 h with a magnetic stirrer,
which resulted in a solution that appeared homogeneous and
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composed of a single phase. The solution was left overnight, and a
further 30 min of sonication was applied the following morning in
order to conﬁrm the uniformity of the solution. For the irgasan-
loaded solutions, the same method was applied, at a concentration
of 1% irgasan w/w. The concentration of the levoﬂoxacin-loaded
solutions was adjusted to 0.5% w/w to facilitate accurate
measurement of the drug release proﬁle. All the solutions
remained clear after preparation. This process was based on the
method used by Hall Barrientos et al. (2016) for solution
preparation (Hall Barrientos et al., 2016).
2.3. Electrospinning
Various scaffolds were fabricated for each polymeric solution,
using an in-house electrospinning apparatus which consisted of a
syringe pump (Harvard Apparatus PHD 2000 infusion, US) and two
30 kV high-voltage power supplies (Alpha III series, Brandenburg,
UK). The polymer solution was loaded into a 5 ml glass syringe and
fed through tubing with a metal needle tip attached at the end. The
needle was clamped into place, to allow for a high-voltage supply
to run through it  this allowed for an electric ﬁeld to be created
between the needle and the target plate. The syringe was clamped
to a pump, which determined the speciﬁc injection ﬂow rate of the
polymeric solutions. For each of the three solutions (e.g. unloaded,
irgasan loaded, and levoﬂoxacin loaded), 3 varying ﬂow rates of
0.5, 1 and 1.5 ml h1 were applied across varying voltages of 2 kV–
5 kV (across the needles) and 10 kV–18 kV (Hall Barrientos et al.,
2016). A 21 gauge needle, at a deposition distance of between 10
and 12 cm was used. The process was performed at ambient room
temperature (approximately 21 C) with a relative humidity of
between 2 and 4% (electrospinning was not performed if the
relative humidity was greater than 5%). The solution was electro-
spun onto the target that was covered with aluminium foil, in order
for the ﬁnal material to be removed and used for further
characterisation.
2.4. Scanning electron microscopy
A scanning electron microscope (SEM) was used to determine
the morphology and individual ﬁbre diameter of the electrospun
PLA solutions (PLA, PLA-IRG, PLA-LEVO, PLA-Collagen, PLA-
Collagen-IRG, and PLA-Collagen-LEVO). A Hitachi TM-1000 SEM
was used to analyse various samples, in which the samples were
mounted on an aluminium plate with conductive tape. Images of
ﬁbres were taken at various locations of each electrospun PLA
scaffold in order to determine the overall uniformity of ﬁbres
(n = 5). Prior to imaging, the samples were sputter coated with gold
for 30 s using a Leica EM ACE200 vacuum coater, repeated three
times in order to increase the conductivity of the samples. The
samples were imaged in secondary electron mode at 5 kV.
2.5. Mathematical analysis of ﬁbre diameters
Statistical comparisons of samples were conducted using SPSS
20.0 software package (SPSS Inc., Chicago IL, USA). Descriptive
statistics, analysis of variance, Scheffé post hoc test and
Kolgomorov-Smirnov test were performed using 50 individual
ﬁbre diameters of each samples obtained from the morphological
analysis.
2.6. Atomic force microscopy
Further morphological analysis was undertaken through atomic
force microscopy (AFM). A Multimode 8 microscope (Bruker, USA),
with Scanasyst-Air probes (Bruker, USA) was used in Peak Force
Quantitative Nano Mechanics (QNM) mode (Lamprou et al., 2013).
The imaging of the ﬁbres was performed under ambient
conditions, with a silicon cantilever probe (Bruker). The tip radius
of the probe and the spring constant were calculated to be in the
regions of 0.964 nm (18 tip half angle) and 0.3947 N/m,
respectively. The scan sizes ranged from 200 nm to 25 mm, at a
scan rate of 0.977 Hz with 512-sample resolution. The Roughness
Average (Ra) values were determined by entering surface scanning
data, and digital levelling algorithm values were determined using
Nanoscope Analysis software V1.40 (Bruker USA). AFM images
were collected from two different samples and at random spot
surface sampling.
2.7. Differential scanning calorimetry (DSC)
Differential scanning calorimetry (DSC) was carried out using a
Mettler Toledo DSC822 in order to examine the thermal properties
of the electrospun PLA scaffolds. First, the scaffolds were cut,
weighed and placed in the DSC speciﬁc aluminium discs. The disc
was then sealed using a press and subsequently placed in the DSC
instrument. The parameters for DSC analysis were set (parameters
are detailed below) via the computer software. The analysis was
then run which took approximately 20 min. The method included
heating from 25 C to 220 C at 10 C steps, using standard 40 ml
aluminium discs, and each sample consisted of 4 mg.
2.8. X-Ray powder diffraction (XRPD)
XRPD was performed in a Bruker D2 Phaser machine and
measurements were taken under CuKa radiation (l = 1.5406 Å),
40 kV and 30 mA as X-ray source with Kb (Ni) ﬁlter. Diffraction
patterns were collected with 2u ranging from 3 to 70.
2.9. Contact angle goniometry (CAG)
To monitor changes in wettability of the scaffolds, sessile drop
contact angle for distilled water was measured by contact angle
goniometry, using a contact angle goniometer (Kruss G30,
Germany) (Lamprou et al., 2010).
2.10. Surface energy analysis
The dispersive surface energy of the raw drug samples was
determined by inverse gas chromatography using a SEA–IGC
(Surface Measurement Systems). The samples were packed into
30 cm (3 mm inside diameter) silanised glass columns, plugged at
either end by silanised glass wool. Various dispersive probes were
used; undecane, decane, nonane, octane, heptane, and hexane
were injected at a range of fractional surface coverage in order to
determine the concentration free dispersive surface energy
(Gamble et al., 2012).
2.11. 1H NMR studies
NMR spectra were recorded on a Varian 600 MHz spectrometer
at 298.2  0.1 K with CDCl3:DMF (N,N-dimethylformamide), 95:5,
V/V% as solvent, using tetramethylsilane (TMS) as the chemical
shift reference compound. The sample volume was 600 ml.1H NMR
spectra were recorded with the pulse and acquire sequence
(number of transients = 16, number of points = 16384, acquisition
time = 851.968 ms, relaxation delay = 1.5 s).
2.12. In vitro drug release studies
The drug releases of the irgasan/levoﬂoxacin loaded PLA-blend
scaffolds were measured in order to determine the release proﬁle
for each drug. Buffer solutions consisting of phosphate buffer
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solution (PBS, pH 7.4) was mixed with 1% sodium dodecyl sulphate
(SDS, a surfactant was used due to the hydrophobic nature of
irgasan). The UV absorbance of both drugs were measured (irgasan
at 280 nm (Rafqah et al., 2006), and levoﬂoxacin at 293 nm
(Shahwal et al., 2013), respectively) at various time points (e.g.
15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 24 h and then every day up to
192 h). For every measurement 3 ml of solution was taken from the
vial (consisting of total 6 ml PBS) and replaced with fresh 3 ml
buffer in order to satisfy the perfect-sink conditions. The samples
were stored in a temperature room of 37 C.
2.13. Antibacterial studies
The antibacterial efﬁcacy of the drug loaded electrospun
scaffolds were tested with Escherichia coli (E. coli) 8739 and
Staphylococcus aureus (S. aureus) 29213, bacterial strains represen-
tative of gram-negative and gram-positive bacteria, respectively.
For this study, a disc agar diffusion method was used. Luria-Bertani
(LB) agar was prepared with the LB medium consisting of 5 g
tryptone, 2.5 g yeast extract, 5 g NaCl and 475 ml of deionized
water. The E. coli and S. aureus cultures were grown overnight in
5 ml of solution, with both bacteria inoculated from a single colony.
150 ml of the E. coli and S. aureus cultures were spread onto plates
of LB agar. 6 plates received an E. coli inoculum, and the other 6
plates contained the S. aureus inoculum, before adding small pieces
of scaffold onto each plate. Scaffolds containing no drug and no
scaffold presence acted as controls. Each scaffold was placed in
triplicate to ensure accurate results. The plates were left for
incubation for 48 h, and subsequently examined at 24 h and 48 h.
Diameters of zones in which there was no bacterial growth were
measured, and these were compared across the various drugs and
bacterial strains.
2.14. Time of ﬂight secondary ion mass spectrometry (ToF-SIMS)
The analyses were carried out with a ToF-SIMS V instrument
(ION-TOF GmbH, Münster, Germany) equipped with a Bismuth
cluster Liquid Metal Ion Gun (LMIG). To overcome charge build-up
on the isolative samples, a low-energy electron beam (21 eV) ﬂood
gun was employed and the sample surface potential was optimised
for each analysis.
Spectrometry mode was applied to acquire reference spectra of
Levoﬂoxacin, Irgasan and PLA. Data was recorded in three
replicates for both polarities and each acquisition was made from
different areas of the samples used in this study, over a ﬁeld of view
of 100 mm  100 mm. The 30 kV Bi3
+ primary ion beam was
optimised to deliver a ﬁnal primary ion dose density (PIDD) of
8.0  1012 (primary ions/cm2) for each spectrum.
High lateral resolution images of the four drug-loaded
samples were collected over a surface area of 50 mm  50 mm,
with a resolution of 512  512 pixels (pixel width was circa
0.1 mm), in the negative secondary ion polarity, with a ﬁnal PIDD
equal to 8.0  1012 primary ions/cm2. The images were then
processed using SurfaceLab 6.7 software (ION-TOF, Münster,
Germany). All the mass spectral information was recorded in
the m/z range of 0–900 Da.
3. Results
3.1. Intermolecular interactions
Preliminary 1H NMR study performed in liquid phase suggests
the absence of any speciﬁc intermolecular interaction between PLA
and LEVO. The 1H NMR spectrum of polylactic revealed two well-
deﬁned peaks centered at 5.10 and 1.52 (ppm) with smaller peaks
residing in the vicinity of the main signal (less than 2% in total peak
Fig. 1. The 1H NMR spectrum of polylactic acid in CDCl3:DMF, 95:5, V/V%.
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area based on Lorentz peak ﬁtting) as depicted in Fig. 1. The
relatively sharp (2–3 Hz half width) and uniform quartet and
doublet signals of polylactic acid indicate a well-deﬁned confor-
mation throughout the polymer chain, and albeit the varying chain
length the chemical environment of most monomer units is
implied to be highly similar allowing for high mobility on account
of the narrow peaks, i.e. high T2. The peaks at 7.26, 7.94, 2.89, and
2.81 are that of CHCl3, the formyl hydrogen of DMF, and the two
methyl peaks of DMF, respectively. The 1H NMR spectrum of
polylactic acid doped with 0.1% levoﬂoxacin showed no difference
in the NMR parameters of the polymer; the peaks of levoﬂoxacin
were detected at the expected chemical shift ranges, however
these signals appeared with too low SNR to be useful for further
measurements. It can only be inferred from the NMR measure-
ments that a possible presence of intermolecular interaction
between polylactic acid and levoﬂoxacin does not bring about
detectable changes in the 1H NMR spectra.
3.2. Fibre morphology
A one-way between-groups analysis of variance (ANOVA)
indicated that there are signiﬁcant differences (p < 0.001) between
the investigated formulations. Applying Scheffé post-hoc compar-
ison, signiﬁcant differences were conﬁrmed between samples
except for PLA compared with PLA-IRG and PLA-Collagen
compared with PLA-Collagen-IRG. The latter was also corroborated
by the overlap between the obtained conﬁdence intervals; whilst
in case of the other samples the conﬁdence intervals are separated
from each other. Except for PLA-Collagen-LEVO, 99.7% of the
measured ﬁbre diameters fall between the range of mean  3 SD,
and similarities of the mean and median values suggest that these
samples are normally distributed (Fig. 2).
Fibre diameter histograms were assayed using Kolgomorov-
Smirnov test (p < 0.01) of equality of distributions (Table 2), which
indicated that there is no signiﬁcant difference, when PLA
compared with PLA-IRG; and PLA-Collagen compared with PLA-
Collagen-IRG. On the other hand, distributions of PLA/PLA-IRG;
PLA-Collagen/PLA-Collagen-IRG; PLA-LEVO; PLA-Collagen-LEVO
were signiﬁcantly different when compared with each other. It
must be noted that PLA-Collagen-LEVO exhibited the highest
coefﬁcient of variation (72.7%), whilst PLA-LEVO had the lowest
value (17.2%) (Table 1).
The SEM images (Fig. 3) demonstrated a range of morphologies
across both polymer-drug and polymer-collagen-drug electrospun
scaffolds. The PLA-drug scaffolds (Fig. 3a–c) showed consistent
ﬁbre diameter and the addition of IRG and LEVO caused very slight
beading within the ﬁbres.
The AFM images (Fig. 4) show the morphology of the ﬁbres at a
greater detail and resolution. PLA-drug scaffolds (Fig. 4a–b) show a
slight variation of morphology across their surfaces; PLA ﬁbres
have a relatively smooth surface with what appears to be beading
(possible solvent residue) on the surface, PLA-IRG ﬁbres generally
showed smooth morphology with no signs of active pharmaceuti-
cal ingredient (API) or solvent residue on the surface, whereas the
PLA-LEVO ﬁbres showed a rougher morphology which may have
resulted from crystals of the drug at the surface  this observation
was supported by the release proﬁle (see: Results, Drug Efﬁcacy).
The surface morphology for the PLA-collagen-drug scaffolds
Fig. 2. Histograms of ﬁbre diameters (a) PLA Unloaded, (b) PLA-IRG, (c) PLA-LEVO, (d) PLA-Collagen (e) PLA-Collagen-IRG, and (f) PLA-Collagen-LEVO.
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(Fig. 4d–f) showed the presence of collagen “wrapping” the
polymeric ﬁbres in a helical manner. This morphology was
consistent throughout, which may highlight a helical coating of
the collagen through the fabricated scaffolds. There appeared to be
no presence of drug on the surface of these ﬁbres.
3.3. Solid state characterisation
The graphs in Fig. 5indicate the various DSC isotherms for PLA-
drug ﬁbres (Fig. 5a), and PLA-Collagen ﬁbres (Fig. 5b). For most of
the samples, the glass transition temperature (Tg) is observed
around 60 C, the crystallisation temperature (Tc), an exothermic
peak, is observed around 90–115 C and the melting point, an
endothermic peak, is observed at 145 C. Overall the Tc for PLA-
drug samples is lower than the PLA-collagen-drug samples. In the
case of PLA-IRG (Fig. 5a), the Tg appears to be suppressed and a Tc
was not measured at all.
XRPD data shown in Fig. 6 indicate that PLA ﬁbres are semi-
crystalline, indicated by broad region, followed by a sharp peak at
17. It can be observed in Fig. 6a that the addition of IRG causes an
increase in the crystallinity of the polymer-drug sample, due to the
sharp polymer peak at 17. There are no signiﬁcant peaks arising
within the PLA-IRG graph related to the IRG intensity. The PLA-
collagen-IRG graph indicates that the sample is in an amorphous
state, due to the very broad peak observed from 5 to 25. The
graphs relating to the PLA-LEVO sample (Fig. 6b) show two
signiﬁcant peaks at 7 (relating levoﬂoxacin) and 17 (relating
to PLA). Again, the addition of collagen to these samples resulted in
a broad amorphous peak ranging from 5 to 25.
3.4. Surface analysis
The dispersive surface energy of powder irgasan was measured
at 37.32 mJ/m2, and a BET speciﬁc surface area of 0.0103 m2/g.
Table 1
Descriptive statistics of the electrospun ﬁbre diameters.
N Mean Std. Deviation Std. Error 95% Conﬁdence Interval for Mean Minimum Maximum Median Coefﬁcient of variation%
Lower Bound Upper Bound
PLA 50 2.73 0.38 0.05 2.62 2.84 1.86 3.62 2.73 30.70
PLA-IRG 50 2.48 0.64 0.09 2.29 2.66 1.28 3.78 2.42 25.90
PLA-LEVO 50 2.08 0.36 0.05 1.98 2.18 1.32 3.08 2.08 17.20
PLA-Collagen 50 1.67 0.41 0.06 1.55 1.78 1.06 3.02 1.57 24.47
PLA-Collagen-IRG 50 1.70 0.50 0.07 1.56 1.84 1.01 3.63 1.64 29.42
PLA-Collagen-LEVO 50 0.98 0.71 0.10 0.78 1.18 0.12 3.67 0.92 72.67
Table 2
Multiple Comparisons.
(I) adat Mean Difference (I-J) Std. Error Sig. 95% Conﬁdence Interval
Lower Bound Upper Bound
PLA PLA-IRG 0.2575600 0.1034985 0.291 0.089176 0.604296
PLA-LEVO 0.6521600* 0.1034985 0.000 0.305424 0.998896
PLA-COLLAGEN 1.0665800* 0.1034985 0.000 0.719844 1.413316
PLA_COLLAGEN_IRG 1.0354800* 0.1034985 0.000 0.688744 1.382216
PLA_COLLAGEN_LEVO 1.7551000* 0.1034985 0.000 1.408364 2.101836
PLA-IRG PLA 0.2575600 0.1034985 0.291 0.604296 0.089176
PLA-LEVO 0.3946000* 0.1034985 0.014 0.047864 0.741336
PLA-COLLAGEN 0.8090200* 0.1034985 0.000 0.462284 1.155756
PLA_COLLAGEN_IRG 0.7779200* 0.1034985 0.000 0.431184 1.124656
PLA_COLLAGEN_LEVO 1.4975400* 0.1034985 0.000 1.150804 1.844276
PLA-LEVO PLA 0.6521600* 0.1034985 0.000 0.998896 0.305424
PLA-IRG 0.3946000* 0.1034985 0.014 0.741336 0.047864
PLA-COLLAGEN 0.4144200* 0.1034985 0.008 0.067684 0.761156
PLA_COLLAGEN_IRG 0.3833200* 0.1034985 0.019 0.036584 0.730056
PLA_COLLAGEN_LEVO 1.1029400* 0.1034985 0.000 0.756204 1.449676
PLA-COLLAGEN PLA 1.0665800* 0.1034985 0.000 1.413316 0.719844
PLA-IRG 0.8090200* 0.1034985 0.000 1.155756 0.462284
PLA-LEVO 0.4144200* 0.1034985 0.008 0.761156 0.067684
PLA_COLLAGEN_IRG 0.0311000 0.1034985 1.000 0.377836 0.315636
PLA_COLLAGEN_LEVO 0.6885200* 0.1034985 0.000 0.341784 1.035256
PLA_COLLAGEN_IRG PLA 1.0354800* 0.1034985 0.000 1.382216 0.688744
PLA-IRG 0.7779200* 0.1034985 0.000 1.124656 0.431184
PLA-LEVO 0.3833200* 0.1034985 0.019 0.730056 0.036584
PLA-COLLAGEN 0.0311000 0.1034985 1.000 0.315636 0.377836
PLA_COLLAGEN_LEVO 0.7196200* 0.1034985 0.000 0.372884 1.066356
PLA_COLLAGEN_LEVO PLA 1.7551000* 0.1034985 0.000 2.101836 1.408364
PLA-IRG 1.4975400* 0.1034985 0.000 1.844276 1.150804
PLA-LEVO 1.1029400* 0.1034985 0.000 1.449676 0.756204
PLA-COLLAGEN 0.6885200* 0.1034985 0.000 1.035256 0.341784
PLA_COLLAGEN_IRG 0.7196200* 0.1034985 0.000 1.066356 0.372884
* The mean difference is signiﬁcant at the 0.05 level.
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Levoﬂoxacin had a higher dispersive surface energy of 47.34 mJ/m2
and a BET speciﬁc surface area of 0.0481 m2/g.
The contact angle measurements shown in Fig. 7 highlight the
differences across PLA-drug and PLA-collagen-drug combinations;
PLA-LEVO had a lower overall starting and ﬁnishing contact angle
(108 2.11 to 50 2.35, respectively), compared with the PLA
and PLA-IRG (120 1.09 to 80 1.22, respectively). The samples
containing collagen had a greater starting contact angle (130
 3.42) and ﬁnal contact angle reading (120 4.12).
3.5. Drug efﬁcacy and antibacterial studies
The cumulative drug release proﬁles are presented in Fig. 8;
both PLA-IRG and PLA-collagen-IRG samples exhibited sustained
Fig. 3. SEM Images of: (a) PLA Unloaded, (b) PLA-IRG, (c) PLA-LEVO, (d) PLA-Collagen, (e) PLA-Collagen-IRG, and (f) PLA-Collagen-LEVO.
Fig. 4. AFM Images of (a) PLA Unloaded, (b) PLA-IRG, (c) PLA-LEVO, (d) PLA-Collagen (e) PLA-Collagen-IRG, and (f) PLA-Collagen-LEVO.
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release behaviour over 192 h, with a ﬁnal release of 40%. PLA-
LEVO exhibited burst release behaviour, releasing 20% within the
ﬁrst 24 h of measurement. PLA-collagen-LEVO showed a signiﬁ-
cantly lower release percentage initially, however it appeared to
exhibit sustained release behaviour, with a ﬁnal cumulative release
of 25%. The total drug content was determined by Concentration
 Volume of Medium  Dilution Factor/1000 (correction factor).
Therefore, % Drug Release = Amount of Drug/Theoretical Drug
Amount  100.
Antibacterial measurements were taken at 24 h and 48 h (Fig. 9,
48 h only). The PLA-drug samples show a high efﬁcacy to control
the growth of both E. coli and S. aureus. In particular, PLA-LEVO
(2.1 cm) had a higher average inhibition zone than PLA-IRG
(1.0 cm). PLA-collagen-IRG resisted both strains of bacteria in a
similar manner to the PLA-IRG sample (average inhibition zone =
1.1 cm). Finally, the PLA-collagen-LEVO sample showed an average
inhibition zone to E. coli of 1.0 cm; however white spores of
bacteria were re-forming near the sample. This sample also had a
smaller efﬁcacy with inhibiting the growth of S. aureus, demon-
strating an average inhibition zone of 0.4 cm.
3.6. ToF-SIMS
Imaging data showed a difference in the distribution of the APIs
in the various strands. The compounds of interest are identiﬁed by
unique characteristic ion peaks; PLA at m/z 71 ([C3H3O2]
) and m/z
Fig. 5. DSC Curves of (a) PLA-drug, (b) PLA-Collagen-drugs and (c) raw drugs Irgasan and Levoﬂoxacin.
Fig. 6. XRPD Graphs of (a) PLA IRG Blends and (b) PLA LEVO Blends.
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89 ([C3H5O3]
), Levoﬂoxacin at m/z 360 ([C18H19FN3O4]
, [MH])
and m/z 316 ([C17H19FN3O2]
), and Irgasan at m/z 287 ([C12H6
35
Cl3O2]
 [MH]), and isotopes m/z 289 ([C12H6
35 Cl2
37 ClO2]
) and
m/z 291 ([C12H6
35 Cl37 Cl2O2]
). The total ion images and the
overlays of single ion images for the characteristic peaks of PLA,
PLA-collagen and the two drugs are reported in Fig. 10. With
regards to the PLA-IRG and PLA-LEVO electrospun scaffolds, by the
ion images Irgasan appears to be homogeneously distributed
throughout the sample, whilst the presence of Levoﬂoxacin is
concentrated in multiple small regions on the surface of the ﬁbers.
This conﬁrms the data obtained with the AFM analysis and with
the release study  (see: Results, Fibre Morphology and Results,
Drug Efﬁcacy).
The diagnostic peaks for both the APIs in the PLA-collagen-API
samples present normalized intensities which are 2 to 3 times lower
than the corresponding peaks in the PLA-API samples, making it
difﬁcult to comment on their distribution. The reduced signal could
be caused by matrix effects, an artefact of ionization. Here, it is
possible that the presence of collagen in the system suppressed the
ionization of the APIs. Alternatively, it could suggest a lower
concentration of the APIs present on the surface of the PLA-Collagen
ﬁbres compared to the PLA ones, and could be interpreted as a better
embedding of the APIs into the strands.
4. Discussion
4.1. Fibre morphology
The differences in ﬁbre form between PLA-drug and PLA-
collagen-drug samples can be clearly seen in Figs. 2 and 3, where
the addition of collagen has created smaller diameters of the ﬁbres.
This is due to the nature of collagen ﬁbre formation, which usually
form nanoﬁbres of around 100 nm (Matthews et al., 2002).
Although, the ﬁbres created in this study are signiﬁcantly bigger
than other studies (e.g. average collagen ﬁbres diameters = 400
nm (Buttafoco et al., 2006)) this may be largely due to the blend of
PLA and collagen  with PLA-drug solutions producing ﬁbres with
a diameter greater than 2 mm. Fibre formation may also be more
effective with collagen, due to the HFP solvent; the low boiling
point (58.2 C) of this solvent allows for a quicker evaporation
during the electrospinning process, which in turn means that the
ﬁbres are being deposited in a dry state. HFP is also a denaturing
organic solvent, and therefore the interaction between solvent and
collagen may cause change in the structure of the proteins (Guo
et al., 2013). When compared to polycaprolactone ﬁbres (as
conducted in our previous study) electrospun in similar conditions,
the addition of levoﬂoxacin increased the overall average ﬁbre
diameter (PCL = 1.83 mm (Del Valle et al., 2011) PCL-LEVO = 2.8
mm (Hall Barrientos et al., 2016)).
It was also observed that the addition of levoﬂoxacin within
both PLA and PLA-collagen blends resulted in a decreased average
ﬁbre diameter; this can be linked to the rheological behaviour of
the solutions where levoﬂoxacin increased the viscosity of the
solution, which normally results in a change in ﬁbre size (Song
et al., 2012). There also appears to be evidence of levoﬂoxacin
appearing at the surface of the ﬁbres (Fig. 4c), however this may be
expected for this particular drug due to the high dispersive surface
energy (see Results: Surface Analysis). If the drug has a high surface
energy, this affects the viscosity of the solution, which in turn
alters the surface tension.
The AFM images of the polymer-collagen blends revealed a
helical pattern of collagen around the ﬁbres  the ﬁbrils of collagen
exhibit a repeating, nano-banding pattern. Collagen naturally
forms a coiled structure, and the underlying alpha chains within
the collagen ﬁbrils could be responsible for the repeating banding
pattern observed (Barnes et al., 2007). This may be useful within a
tissue engineering context, given that this repeat banding is
thought to expose a binding site in the native collagen ﬁbril that
enhances cell adhesion and migration (Sell et al., 2009).
4.2. Solid state characterisation
The DSC data was vital in understanding any potential chemical
interactions between the drug and polymer. In Fig. 5, the PLA-IRG
plot, shows that there is no visible exothermic reaction (Tc)
occurring after the initial glass transition phase, and also no
indication of the Tm of the raw IRG drug at around 60 C  this can
interpreted as the IRG being fully integrated within the polymeric
structure (Kayaci et al., 2013). The Tc values recorded were greater
in the samples containing collagen which may be attributed to
dehydration of the collagen (Bozec and Odlyha, 2011). This may be
indicative of the collagen successfully embedding or interacting
with the polymer. A reduction in the Tg at around 60 C of the PLA-
Collagen-LEVO can be observed, which again may indicate that
there is no presence of free LEVO particle in this sample  this is
perhaps why a sustained release behaviour is observed in
Section 4.4 (drug efﬁcacy).
The data presented by the DSC was effectively conﬁrmed
through the XRPD data (Fig. 6). The PLA-IRG sample can be seen to
remain in a near semi-crystalline form (slight broad peak, followed
by sharp crystalline PLA peak), with no IRG peaks. It can be
Fig. 7. CAG Data for PLA-Drug and PLA-Collagen-Drug blends. Fig. 8. Drug release proﬁles of PLA-drug and PLA-collagen-drug scaffolds.
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concluded from this that the IRG is fully embedded within the
polymeric network. Similarly, no IRG peaks were visible within the
PLA-collagen-IRG graph; however, the broad peak does indicate
that the material is in an amorphous form. The PLA-LEVO graph
showed a peak, indicating that the drug is still in crystalline form
and is not incorporated uniformly into the polymeric network. A
similar amorphous peak was observed in the PLA-collagen-LEVO
peak, which may indicate a better encapsulation of drug.
4.3. Surface analysis
Understanding the surface energy of the drug molecules was an
important part of this study, since it has successfully helped to
understand the reasons behind particular behaviour relating to
ﬁbre morphology and overall drug encapsulation. The surface
energy analysis of the two drugs indicated a higher dispersive
surface energy for levoﬂoxacin compared with irgasan. Given that
IRG and LEVO are both in a crystalline form, and that polylactic acid
is naturally semi-crystalline, there may be an increased possibility
of the two drugs integrating into the polymeric matrix. The two
drugs may require a higher energy in order to disperse properly
within the PLA polymeric structure. With irgasan having a lower
dispersive surface energy and a hydrophobic nature, there may be
a reduced energy requirement for this drug to properly disperse
within a solvent solution. If levoﬂoxacin has a higher dispersive
surface energy, then the transfer of energy between LEVO and
solvent will be insufﬁcient to overcome the drug–drug attractions.
Therefore, not all the levoﬂoxacin molecules in solution will be
surrounded by solvent molecules and dispersed fully into solution
(Shah et al., 2017). At equilibrium, hydrophobic molecules
preferentially partition into the organic phase, typically due to a
high log P value (Vorng et al., 2016)  the log P of levoﬂoxacin is
1.27 (Anon., 2008a) and the log P of Irgasan is 4.76 (Anon., 2008b).
Based on the positive values on the log P, both drugs are
hydrophobic and Irgasan is more hydrophobic than LEVO. With
both drugs and PLA exhibiting a hydrophobic nature, this suggests
that hydrophobic interactions might occur between the materials.
If the hydrophobic interactions are a dominant, this should be
more advantageous in increasing encapsulation efﬁciency (Jeyan-
thi et al., 1997).
The change in contract angle may reﬂect the encapsulation of
both drugs within the polymer matrix. It can be clearly seen in
Fig. 7 that the contact angle was lowest for the PLA-LEVO sample.
This can be attributed to the lower hydrophobic nature of
levoﬂoxacin, the high dispersive surface energy and the probability
of the drug on the surface of the ﬁbres (see Results: Fibre
Morphology, AFM). With the PLA-collagen-drug samples, the
contact angles are greater, implying that the samples are more
hydrophobic. These results differ from the contact angle measure-
ments in other studies, in particular collagen is found to have
previously increased the hydrophilicity of PLA samples (Ahmed
et al., 2015). It may be the case that the collagen ﬁbrils have
interacted within the polylactic acid based nanoﬁbre. This strong
hydrophobic connection may be linked to the better integration of
both irgasan and levoﬂoxacin.
4.4. Drug efﬁcacy
The release proﬁles of both irgasan and levoﬂoxacin are similar
to the results in a previous study using polycaprolactone (Hall
Barrientos et al., 2016). However, the ﬁnal cumulative release
percentages with Polylactic acid appear to be lower (Final PCL
scaffolds drug release 50%, PLA scaffolds 20% to 40%). This may
suggest a poorer drug encapsulation with PLA, which may be due
to the fact that PLA is more hydrophilic than PCL (Patrício et al.,
2013). The hydrophobic interactions between PLA and IRG may
potentially be the cause of the sustained release behaviour in vitro,
and the lower hydrophobic nature of LEVO may be an even further
reduction in a strong polymer-drug interaction. As mentioned in
the surface analysis section, the higher dispersive surface energy
may cause this weak interaction between PLA and LEVO; AFM
images in Fig. 4 indicating the possible presence of drug at the
surface of the ﬁbres. This presence of drug at the surface would
result in a rapid uptake of water, and therefore be the reason
behind the burst release behaviour observed in vitro. The addition
of type I collagen to the polymer-drug samples resulted in a
difference in release behaviour with LEVO  this drug released in a
sustained release time proﬁle, implying that collagen may be
directly affecting the release of the drug. Literature evidence
suggests that the hydrophilic, carboxyl functional groups in the
polymer could be interacting with basic functions expressed by the
collagen (Cheng and Teoh, 2004) which in turn results in a change
in the hydrophobicity of the ﬁbre, which may result in the
sustained release time proﬁle for the levoﬂoxacin with the PLA-
collagen sample.
The antibacterial studies were consistent with the drug release
proﬁles, and indicated that the formulations were effective in
inhibiting the growth of E. coli and S. aureus. The larger zones of
inhibition can be seen in the PLA-LEVO sample, which exhibits
burst release behaviour. The smaller inhibition zones for PLA-IRG
and PLA-collagen-IRG were indicative of the sustained release
proﬁles. The sustained release proﬁle of PLA-collagen-LEVO was
Fig. 9. Images of antibacterial growth after 48 h. (a) PLA-IRG against E. Coli, (b) PLA-IRG against S. Aureus, (c) PLA-LEVO against E. Coli, (d) PLA-LEVO against S. Aureus, (e) PLA-
Collagen-IRG against E. Coli, (f) PLA-Collagen-IRG against S. Aureus, (g) PLA-Collagen-LEVO against E. Coli, and (h) PLA-Collagen-LEVO against S. Aureus.
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Fig. 10. ToF-SIMS data of (a) PLA-IRG, (b) PLA-LEVO, (c) PLA-Collagen-IRG, and (d) PLA-Collagen-LEVO.
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also conﬁrmed, given that there were small areas of bacterial
growth  this can be attributed to the low cumulative release
percentage at 48 h of the study by which time <10% of the drug had
been released).
4.5. ToF-SIMS
The visualisation of the distribution of the APIs on the sample
surface contributed to gain a better understanding about the
degree of drug encapsulation and in general about the interactions
between the drugs and the ﬁbres. This result concurs with the
suggested explanation with regards to the release behaviour and is
consistent with the results from the other techniques described in
this paper.
5. Conclusion
It can be seen that the inclusion of type I collagen signiﬁcantly
altered various characteristics of electrospun polymer-drug scaf-
folds. The addition of collagen caused an overall decrease in ﬁbre
morphology and average ﬁbre diameter across both sets of drugs,
irgasan and levoﬂoxacin, with nanoﬁbers forming in the PLA-
collagen-LEVO samples. AFM images revealed collagen ﬁbril
banding on the surface of the ﬁbres which suggest there is an
interaction between the polymer-drug and collagen. There were
also changes in the solid-state characteristics of the samples, given
that the DSC results indicate an increase in amorphousness of the
polymer-drug-collagen samples, and this was conﬁrmed through
typically broad peaks in the XRPD results. Most interestingly, the
surface energies of the scaffolds were modiﬁed with an increase in
the hydrophobicity of the polymer-collagen-drug noted. In
particular, the PLA-collagen-LEVO sample showed a high deal of
hydrophobicity, which was unusual given the low hydrophobic
nature of LEVO  this could potentially be attributed to the strong
hydrophobic interactions between the PLA and the hydrophobic
banding in collagen ﬁbrils, resulting in better encapsulation of the
drug. Finally, the drug release proﬁles of the samples appear to
change due to the inclusion of collagen, most signiﬁcantly
demonstrating the shift of the burst release behaviour in PLA-
LEVO to sustained release behaviour within PLA-collagen-LEVO
samples. This study is important in demonstrating that the
modiﬁcation of electrospun scaffolds can be achieved by incorpo-
rating natural polymers, such as collagen  and this modiﬁcation
may be useful in the compatibility and utilisation of tissue
engineered structures within the human body.
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